Identification of a Small-Molecule Inhibitor of Class Ia PI3Ks with Cell-Based Screening

Chemistry and Biology

Volumn 14, Issue 4, 2007, Pages 371-377

  Yang, Jiong ^a   Shamji, Alykhan ^a   Matchacheep, Sirinya ^a   Schreiber, Stuart L ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

CHEMBIOL; SIGNALING

Indexed keywords

FUSED HETEROCYCLIC RINGS; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN S6; QUINOLINE DERIVATIVE; QUINOSTATIN; S6 KINASE; UNCLASSIFIED DRUG;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVE SITE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC DOMAIN; CELL LINE, TUMOR; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; PHOSPHORYLATION; PROTEIN KINASES; QUINOLINES; RIBOSOMAL PROTEIN S6; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

MAMMALIA;

EID: 34247211775     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2007.02.004     Document Type: Article

References (27)

1. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
2. Shamji A.F., Nghiem P., and Schreiber S.L. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol. Cell 12 (2003) 271-280
3. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., and Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA 101 (2004) 13489-13494
4. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005) 179-193
5. -/- mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24 (2004) 3112-3124
6. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
7. Nobukuni T., Joaquin M., Roccio M., Dann S.G., Kim S.Y., Gulati P., Byfield M.P., Backer J.M., Natt F., Bos J.L., et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. USA 102 (2005) 14238-14243
8. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., and Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369 (1994) 756-758
9. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., and Snyder S.H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78 (1994) 35-43
10. Knight Z.A., Gonzales B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., Loewith R., Stokoe D., Balla A., Toth B., et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125 (2006) 733-747
11. Kuruvilla F.G., Shamji A.F., Sternson S.M., Hergenrother P.J., and Schreiber S.L. Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays. Nature 416 (2002) 653-657
12. Butcher R.A., Bhullar B.S., Perlstein E.O., Marsischky G., LaBaer J., and Schreiber S.L. Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway. Nat. Chem. Biol. 2 (2006) 103-109
13. Huang J., Zhu H., Haggarty S.J., Spring D.R., Hwang H., Jin F., Snyder M., and Schreiber S.L. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. USA 101 (2004) 16594-16599
14. Grammer T.C., Cheatham L., Chou M.M., and Blenis J. The p70S6K signaling pathways: a novel signalling system involved in growth regulation. Cancer Surv. 27 (1996) 271-292
15. Stockwell B.R., Haggarty S.J., and Schreiber S.L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 6 (1999) 71-83
16. Wissner A., Berger D.M., Boschelli D.H., Floyd Jr. M.B., Greenberger L.M., Gruber B.C., Johnson B.D., Mamuya N., Nilakantan R., Reich M.F., et al. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J. Med. Chem. 43 (2000) 3244-3256
17. Wymann M.P., Bulgarelli-Leva G., Zvelebil M.J., Pirola L., Vanhaesebroeck B., Waterfield M.J., and Panayotou G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16 (1996) 1722-1733
18. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273 (1998) 18623-18632
19. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
20. Vlahos C.H., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
21. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., and Williams R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6 (2000) 909-919
22. Bader A.G., Kang S., Zhao L., and Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5 (2005) 921-929
23. Ward S., Sotsios Y., Dowden J., Bruce I., and Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. 10 (2003) 207-213
24. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
25. Fan Q.-W., Knight Z.A., Goldenberg D.D., Yu W., Mostov K.E., Stokoe D., Shokat K.M., and Weiss W.A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
26. Wan Y., Hur W., Cho C.Y., Liu Y., Adrian F.J., Lozach O., Bach S., Mayer T., Fabbro D., Meijer L., and Gray N.S. Synthesis and target identification of hymenialdisine analogs. Chem. Biol. 11 (2004) 247-259
27. Walsh J.P., Caldwell K.K., and Majerus P.W. Formation of phosphatidylinositol 3-phosphate by isomerization from phosphatidylinositol 4-phosphate. Proc. Natl. Acad. Sci. USA 88 (1991) 9184-9187